Annual CFF
$65.30 M
+$299.60 M+127.87%
31 December 2023
Summary:
Neurocrine Biosciences annual cash flow from financing activities is currently $65.30 million, with the most recent change of +$299.60 million (+127.87%) on 31 December 2023. During the last 3 years, it has risen by +$223.10 million (+141.38%). NBIX annual CFF is now -87.36% below its all-time high of $516.65 million, reached on 31 December 2017.NBIX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$26.40 M
+$319.40 M+109.01%
30 September 2024
Summary:
Neurocrine Biosciences quarterly cash flow from financing activities is currently $26.40 million, with the most recent change of +$319.40 million (+109.01%) on 30 September 2024. Over the past year, it has increased by +$7.60 million (+40.43%). NBIX quarterly CFF is now -94.79% below its all-time high of $506.49 million, reached on 30 June 2017.NBIX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$161.30 M
+$7.60 M+4.50%
30 September 2024
Summary:
Neurocrine Biosciences TTM cash flow from financing activities is currently -$161.30 million, with the most recent change of +$7.60 million (+4.50%) on 30 September 2024. Over the past year, it has dropped by -$215.80 million (-395.96%). NBIX TTM CFF is now -130.36% below its all-time high of $531.25 million, reached on 31 March 2018.NBIX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +127.9% | +40.4% | -396.0% |
| 3 y3 years | +141.4% | +252.0% | -1.2% |
| 5 y5 years | +121.4% | +101.5% | -841.5% |
NBIX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +127.9% | -62.2% | +109.0% | -227.0% | +38.2% |
| 5 y | 5 years | at high | +127.9% | -62.2% | +109.0% | -227.0% | +38.2% |
| alltime | all time | -87.4% | +127.9% | -94.8% | +109.0% | -130.4% | +38.2% |
Neurocrine Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $26.40 M(-109.0%) | -$161.30 M(-4.5%) |
| June 2024 | - | -$293.00 M(-519.2%) | -$168.90 M(-233.0%) |
| Mar 2024 | - | $69.90 M(+97.5%) | $127.00 M(+94.5%) |
| Dec 2023 | $65.30 M(-127.9%) | $35.40 M(+88.3%) | $65.30 M(+19.8%) |
| Sept 2023 | - | $18.80 M(+548.3%) | $54.50 M(+15.7%) |
| June 2023 | - | $2.90 M(-64.6%) | $47.10 M(-120.3%) |
| Mar 2023 | - | $8.20 M(-66.7%) | -$232.20 M(-0.9%) |
| Dec 2022 | -$234.30 M(-955.1%) | $24.60 M(+115.8%) | -$234.30 M(-8.9%) |
| Sept 2022 | - | $11.40 M(-104.1%) | -$257.10 M(-1.5%) |
| June 2022 | - | -$276.40 M(-4631.1%) | -$261.00 M(-1518.5%) |
| Mar 2022 | - | $6.10 M(+238.9%) | $18.40 M(-32.8%) |
| Dec 2021 | $27.40 M(-117.4%) | $1.80 M(-76.0%) | $27.40 M(-117.2%) |
| Sept 2021 | - | $7.50 M(+150.0%) | -$159.40 M(-1.3%) |
| June 2021 | - | $3.00 M(-80.1%) | -$161.50 M(+8.6%) |
| Mar 2021 | - | $15.10 M(-108.2%) | -$148.70 M(-5.8%) |
| Dec 2020 | -$157.80 M(-587.0%) | -$185.00 M(-3525.9%) | -$157.80 M(-498.5%) |
| Sept 2020 | - | $5.40 M(-65.8%) | $39.60 M(-16.3%) |
| June 2020 | - | $15.80 M(+163.3%) | $47.30 M(+32.1%) |
| Mar 2020 | - | $6.00 M(-51.6%) | $35.80 M(+10.5%) |
| Dec 2019 | $32.40 M(+9.8%) | $12.40 M(-5.3%) | $32.40 M(+49.0%) |
| Sept 2019 | - | $13.10 M(+204.7%) | $21.75 M(+53.8%) |
| June 2019 | - | $4.30 M(+65.4%) | $14.14 M(-11.4%) |
| Mar 2019 | - | $2.60 M(+48.4%) | $15.96 M(-45.9%) |
| Dec 2018 | $29.50 M(-94.3%) | $1.75 M(-68.1%) | $29.50 M(-11.5%) |
| Sept 2018 | - | $5.49 M(-10.3%) | $33.35 M(+8.0%) |
| June 2018 | - | $6.12 M(-62.1%) | $30.88 M(-94.2%) |
| Mar 2018 | - | $16.14 M(+188.1%) | $531.25 M(+2.8%) |
| Dec 2017 | $516.65 M(>+9900.0%) | $5.60 M(+85.3%) | $516.65 M(+1.1%) |
| Sept 2017 | - | $3.02 M(-99.4%) | $511.11 M(+0.3%) |
| June 2017 | - | $506.49 M(>+9900.0%) | $509.42 M(>+9900.0%) |
| Mar 2017 | - | $1.53 M(+2330.2%) | $3.86 M(+61.5%) |
| Dec 2016 | $2.39 M(-99.1%) | $63.00 K(-95.3%) | $2.39 M(-27.5%) |
| Sept 2016 | - | $1.33 M(+42.0%) | $3.29 M(+21.8%) |
| June 2016 | - | $936.00 K(+1409.7%) | $2.71 M(-23.3%) |
| Mar 2016 | - | $62.00 K(-93.6%) | $3.53 M(-98.7%) |
| Dec 2015 | $276.99 M(+99.7%) | $968.00 K(+30.8%) | $276.99 M(-0.3%) |
| Sept 2015 | - | $740.00 K(-57.9%) | $277.76 M(+0.1%) |
| June 2015 | - | $1.76 M(-99.4%) | $277.50 M(+0.5%) |
| Mar 2015 | - | $273.52 M(>+9900.0%) | $276.01 M(+99.0%) |
| Dec 2014 | $138.73 M(+2516.6%) | $1.73 M(+257.9%) | $138.73 M(+1.2%) |
| Sept 2014 | - | $484.00 K(+76.6%) | $137.05 M(-1.6%) |
| June 2014 | - | $274.00 K(-99.8%) | $139.23 M(-1.0%) |
| Mar 2014 | - | $136.24 M(>+9900.0%) | $140.58 M(+2551.4%) |
| Dec 2013 | $5.30 M(-93.7%) | $50.00 K(-98.1%) | $5.30 M(-4.3%) |
| Sept 2013 | - | $2.66 M(+63.8%) | $5.54 M(+84.9%) |
| June 2013 | - | $1.63 M(+68.2%) | $3.00 M(+111.8%) |
| Mar 2013 | - | $966.00 K(+235.4%) | $1.42 M(-98.3%) |
| Dec 2012 | $83.70 M(>+9900.0%) | $288.00 K(+144.1%) | $83.70 M(+0.3%) |
| Sept 2012 | - | $118.00 K(+174.4%) | $83.44 M(+0.1%) |
| June 2012 | - | $43.00 K(-99.9%) | $83.36 M(-0.1%) |
| Mar 2012 | - | $83.25 M(>+9900.0%) | $83.48 M(>+9900.0%) |
| Dec 2011 | $286.00 K(-98.7%) | $22.00 K(-51.1%) | $286.00 K(-21.2%) |
| Sept 2011 | - | $45.00 K(-72.2%) | $363.00 K(+6.8%) |
| June 2011 | - | $162.00 K(+184.2%) | $340.00 K(+87.8%) |
| Mar 2011 | - | $57.00 K(-42.4%) | $181.00 K(-99.2%) |
| Dec 2010 | $21.48 M | $99.00 K(+350.0%) | $21.48 M(-31.3%) |
| Sept 2010 | - | $22.00 K(+633.3%) | $31.28 M(+0.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $3000.00(-100.0%) | $31.26 M(+0.0%) |
| Mar 2010 | - | $21.36 M(+115.7%) | $31.26 M(+215.7%) |
| Dec 2009 | $9.90 M(-781.8%) | $9.90 M(>+9900.0%) | $9.90 M(-3700.0%) |
| Sept 2009 | - | $0.00(0.0%) | -$275.00 K(-54.2%) |
| June 2009 | - | $0.00(0.0%) | -$600.00 K(-39.5%) |
| Mar 2009 | - | $0.00(-100.0%) | -$991.00 K(-31.7%) |
| Dec 2008 | -$1.45 M(-102.5%) | -$275.00 K(-15.4%) | -$1.45 M(-102.5%) |
| Sept 2008 | - | -$325.00 K(-16.9%) | $58.94 M(+1.3%) |
| June 2008 | - | -$391.00 K(-15.2%) | $58.19 M(+0.5%) |
| Mar 2008 | - | -$461.00 K(-100.8%) | $57.88 M(+1.2%) |
| Dec 2007 | $57.18 M(+466.9%) | $60.12 M(-5702.8%) | $57.18 M(-1500.8%) |
| Sept 2007 | - | -$1.07 M(+53.5%) | -$4.08 M(-7.7%) |
| June 2007 | - | -$699.00 K(-40.0%) | -$4.42 M(+25.1%) |
| Mar 2007 | - | -$1.17 M(+1.7%) | -$3.54 M(-135.0%) |
| Dec 2006 | $10.09 M(-2.4%) | -$1.15 M(-19.1%) | $10.09 M(-45.5%) |
| Sept 2006 | - | -$1.42 M(-844.7%) | $18.50 M(-22.7%) |
| June 2006 | - | $190.00 K(-98.5%) | $23.92 M(+0.9%) |
| Mar 2006 | - | $12.46 M(+71.3%) | $23.71 M(+129.5%) |
| Dec 2005 | $10.33 M(-71.8%) | $7.27 M(+81.6%) | $10.33 M(+344.8%) |
| Sept 2005 | - | $4.00 M(<-9900.0%) | $2.32 M(-75.5%) |
| June 2005 | - | -$19.00 K(-97.9%) | $9.49 M(-59.3%) |
| Mar 2005 | - | -$922.00 K(+24.6%) | $23.30 M(-36.5%) |
| Dec 2004 | $36.69 M(-82.6%) | -$740.00 K(-106.6%) | $36.69 M(-29.7%) |
| Sept 2004 | - | $11.17 M(-19.0%) | $52.22 M(-77.3%) |
| June 2004 | - | $13.79 M(+10.5%) | $230.16 M(+5.0%) |
| Mar 2004 | - | $12.47 M(-15.6%) | $219.12 M(+3.8%) |
| Dec 2003 | $211.06 M(+3532.1%) | $14.79 M(-92.2%) | $211.06 M(+6.0%) |
| Sept 2003 | - | $189.11 M(+6786.8%) | $199.03 M(+1605.3%) |
| June 2003 | - | $2.75 M(-37.8%) | $11.67 M(+13.8%) |
| Mar 2003 | - | $4.41 M(+60.2%) | $10.25 M(+76.4%) |
| Dec 2002 | $5.81 M(-96.8%) | $2.75 M(+56.9%) | $5.81 M(-96.8%) |
| Sept 2002 | - | $1.76 M(+32.3%) | $182.06 M(+1.1%) |
| June 2002 | - | $1.33 M(-5014.8%) | $180.17 M(-0.4%) |
| Mar 2002 | - | -$27.00 K(-100.0%) | $180.88 M(-0.2%) |
| Dec 2001 | $181.30 M(+92.6%) | $179.01 M(<-9900.0%) | $181.30 M(+93.6%) |
| Sept 2001 | - | -$140.00 K(-106.8%) | $93.65 M(-1.7%) |
| June 2001 | - | $2.05 M(+423.3%) | $95.23 M(+2.1%) |
| Mar 2001 | - | $391.00 K(-99.6%) | $93.30 M(-0.9%) |
| Dec 2000 | $94.13 M(+129.6%) | $91.36 M(+6275.2%) | $94.13 M(+117.0%) |
| Sept 2000 | - | $1.43 M(+1114.4%) | $43.38 M(+2.9%) |
| June 2000 | - | $118.00 K(-90.4%) | $42.14 M(-0.4%) |
| Mar 2000 | - | $1.22 M(-97.0%) | $42.32 M(+3.2%) |
| Dec 1999 | $41.00 M(+2057.9%) | $40.60 M(>+9900.0%) | $41.00 M(>+9900.0%) |
| Sept 1999 | - | $200.00 K(-33.3%) | $300.00 K(-88.0%) |
| June 1999 | - | $300.00 K(-400.0%) | $2.50 M(+31.6%) |
| Mar 1999 | - | -$100.00 K(0.0%) | $1.90 M(0.0%) |
| Dec 1998 | $1.90 M(+171.4%) | -$100.00 K(-104.2%) | $1.90 M(-32.1%) |
| Sept 1998 | - | $2.40 M(-900.0%) | $2.80 M(+833.3%) |
| June 1998 | - | -$300.00 K(+200.0%) | $300.00 K(-40.0%) |
| Mar 1998 | - | -$100.00 K(-112.5%) | $500.00 K(-28.6%) |
| Dec 1997 | $700.00 K(-98.5%) | $800.00 K(-900.0%) | $700.00 K(-333.3%) |
| Sept 1997 | - | -$100.00 K(0.0%) | -$300.00 K(-25.0%) |
| June 1997 | - | -$100.00 K(-200.0%) | -$400.00 K(-101.0%) |
| Mar 1997 | - | $100.00 K(-150.0%) | $42.10 M(-10.0%) |
| Dec 1996 | $46.80 M | -$200.00 K(0.0%) | $46.80 M(-0.4%) |
| Sept 1996 | - | -$200.00 K(-100.5%) | $47.00 M(-0.4%) |
| June 1996 | - | $42.40 M(+783.3%) | $47.20 M(+883.3%) |
| Mar 1996 | - | $4.80 M | $4.80 M |
FAQ
- What is Neurocrine Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual CFF year-on-year change?
- What is Neurocrine Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly CFF year-on-year change?
- What is Neurocrine Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM CFF year-on-year change?
What is Neurocrine Biosciences annual cash flow from financing activities?
The current annual CFF of NBIX is $65.30 M
What is the all time high annual CFF for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual cash flow from financing activities is $516.65 M
What is Neurocrine Biosciences annual CFF year-on-year change?
Over the past year, NBIX annual cash flow from financing activities has changed by +$299.60 M (+127.87%)
What is Neurocrine Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of NBIX is $26.40 M
What is the all time high quarterly CFF for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly cash flow from financing activities is $506.49 M
What is Neurocrine Biosciences quarterly CFF year-on-year change?
Over the past year, NBIX quarterly cash flow from financing activities has changed by +$7.60 M (+40.43%)
What is Neurocrine Biosciences TTM cash flow from financing activities?
The current TTM CFF of NBIX is -$161.30 M
What is the all time high TTM CFF for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM cash flow from financing activities is $531.25 M
What is Neurocrine Biosciences TTM CFF year-on-year change?
Over the past year, NBIX TTM cash flow from financing activities has changed by -$215.80 M (-395.96%)